Determine the Haemostatic Efficacy of TT-173, Reducing the Bleeding Time in the Donor Site of Skin Grafting

Inclusion Criteria: * Subjects who signed the informed consent. * Subjects that have to undergo a skin graft. * Subjects of both sexes older than 18 years. * Subjects that present a burn or traumatic skin injury affecting less than 30% of corporal surface. * Subjects with a platelet count not compatible with pathology. * Subjects who present haemogram results not indicative of any of the situations mentioned in the exclusion criteria. * Subjects who present biochemical results not indicative of any of the situations mentioned in the exclusion criteria. * Subjects who present coagulation parameters not indicative of any of the situations mentioned in the exclusion criteria. * Women of childbearing age who take contraceptive measures and are willing to maintain them until the end of follow up of this study. * Women of childbearing age who present a negative test pregnancy at the moment of study inclusion Exclusion Criteria: * -Subjects with personal or family history of abnormal hemorrhagic episodes. * Subjects affected of any kind of congenital or acquired coagulopathies. * Subjects that present a burn or traumatic skin injury affecting more than 31% of corporal surface. * Subjects affected of any blood, heart or liver disease, chronic renal failure, severe chronic obstructive pulmonary disease, active oncologic process in the past three months, diabetes type I or who has suffered a stroke. * Subjects who experienced excessive bleeding after surgical procedures, childbirth or tooth extraction. * Subjects affected by any acute infectious disease. * Subjects affected of any systemic disease that may worsen the prognosis if any adverse effect occurs (decompensated type 2 diabetes mellitus, uncontrolled hypertension or severe systemic disease). * Subjects who should take antiplatelet therapies one week before and 48 hours after the surgery (AAS, trifusal, dipiridamol, clopidogrel, abciximab). * Subjects with known hypersensitivity or allergy to any component of the drug. * Subjects who consume abuse drugs excluding cannabis and its derivatives. * Subjects who are unable to follow or understand properly the instructions and requirements of the study. * Subjects who are not free to give informed consent or who are mentally incapacitated to the discretion of investigators. * Subjects who participate or have participated in the past three months in another clinical trial with drug treatment. * Subjects that are the investigators, collaborators, nurses, center employees or any other person directly related to the development of the protocol. * Subjects who are positive to HIV or HCV serology, or who present active HBV infection. * Subjects who are pregnant or lactating.